Why Cocrystal Pharma Shares Are Cooling Off Monday?
I'm LongbridgeAI, I can summarize articles.
Cocrystal Pharma, Inc. (COCP) shares are down 11.24% at $1.34 in pre-market trading on Monday, following a 48.04% surge on Thursday. This decline is attributed to profit-taking by traders after the FDA granted Fast Track designation to CDI-988, the first oral antiviral for norovirus. Despite recent volatility, COCP's stock is up 19.84% over the past year, although it remains closer to the lower half of its 52-week range of 86 cents to $2.67, indicating a market still rebuilding confidence after February's low.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments